207 related articles for article (PubMed ID: 2552901)
1. In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains.
Bush LM; Boscia JA; Wendeler M; Pitsakis PG; Kaye D
Antimicrob Agents Chemother; 1989 Aug; 33(8):1198-200. PubMed ID: 2552901
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activity of daptomycin (LY146032) and vancomycin against gram-positive cocci determined using a pharmacokinetic model.
Blenkharn JI; Darrell JH
Eur J Clin Microbiol Infect Dis; 1989 Aug; 8(8):734-7. PubMed ID: 2550236
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs.
Hanberger H; Nilsson LE; Maller R; Isaksson B
Antimicrob Agents Chemother; 1991 Sep; 35(9):1710-6. PubMed ID: 1659305
[TBL] [Abstract][Full Text] [Related]
4. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model.
LaPlante KL; Rybak MJ; Leuthner KD; Chin JN
Antimicrob Agents Chemother; 2006 Apr; 50(4):1298-303. PubMed ID: 16569844
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci.
Machka K; Braveny I
Eur J Clin Microbiol; 1987 Feb; 6(1):96-9. PubMed ID: 3032613
[TBL] [Abstract][Full Text] [Related]
6. In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis.
Coudron PE; Johnston JL; Archer GL
J Antimicrob Chemother; 1987 Oct; 20(4):505-11. PubMed ID: 2824426
[TBL] [Abstract][Full Text] [Related]
7. Comparative in-vitro activity of LY146032 and eight other antibiotics against gram-positive bacteria isolated from children.
Kline MW; Mason EO; Kaplan SL; Lamberth LB; Johnson GS
J Antimicrob Chemother; 1987 Aug; 20(2):203-7. PubMed ID: 2822647
[TBL] [Abstract][Full Text] [Related]
8. LY146032: activity and resistance development in vitro.
Mouton RP; Mulders SL
J Antimicrob Chemother; 1987 Oct; 20(4):513-7. PubMed ID: 2824427
[TBL] [Abstract][Full Text] [Related]
9. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations.
Brauers J; Kresken M; Menke A; Orland A; Weiher H; Morrissey I
Int J Antimicrob Agents; 2007 Mar; 29(3):322-5. PubMed ID: 17204403
[TBL] [Abstract][Full Text] [Related]
10. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
11. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species.
DeRyke CA; Sutherland C; Zhang B; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2006 Nov; 50(11):3529-34. PubMed ID: 17065618
[TBL] [Abstract][Full Text] [Related]
12. Activity of daptomycin against enterococci and coagulase-negative staphylococci (CNS): relationship between CNS susceptibility and slime production.
Marone P; Perversi L; Navarra A; Monzillo V; Sartirana E
J Chemother; 1993 Jun; 5(3):151-4. PubMed ID: 8396625
[TBL] [Abstract][Full Text] [Related]
13. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.
LaPlante KL; Rybak MJ
Antimicrob Agents Chemother; 2004 Dec; 48(12):4665-72. PubMed ID: 15561842
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria.
Jorgensen JH; Maher LA; Redding JS
Eur J Clin Microbiol; 1987 Feb; 6(1):91-6. PubMed ID: 3032612
[TBL] [Abstract][Full Text] [Related]
15. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms.
Benson CA; Beaudette F; Trenholm G
J Antimicrob Chemother; 1987 Aug; 20(2):191-6. PubMed ID: 2822645
[TBL] [Abstract][Full Text] [Related]
16. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Tsuji BT; Rybak MJ
Antimicrob Agents Chemother; 2005 Jul; 49(7):2735-45. PubMed ID: 15980344
[TBL] [Abstract][Full Text] [Related]
17. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.
Stratton CW; Liu C; Weeks LS
Antimicrob Agents Chemother; 1987 Aug; 31(8):1210-5. PubMed ID: 2820300
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin.
Van der Auwera P
Antimicrob Agents Chemother; 1989 Oct; 33(10):1783-90. PubMed ID: 2556079
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
20. Turbidimetric response of Staphylococcus aureus and Enterococcus faecalis to daptomycin.
Wale MC; Wale LJ; Greenwood D
Eur J Clin Microbiol Infect Dis; 1988 Dec; 7(6):809-12. PubMed ID: 2850913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
